Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada.
Inflamm Res. 2010 Aug;59(8):667-78. doi: 10.1007/s00011-010-0179-3. Epub 2010 Mar 28.
The objective of this study was to determine the ability of meloxicam prophylaxis and therapy to blunt the effect of complete Freund's adjuvant (CFA) induced monoarthritis.
First the validity of this animal model was established by examining joint changes at multiple levels after injecting CFA into the tibio-tarsal joint. Next, meloxicam (5 mg/kg) or vehicle was administered on days 0-7 (prophylactic) and on days 7-16 (therapeutic) in separate groups of animals.
The CFA-injected joint demonstrated hallmark histological and structural changes such as pannus formation, bone remodeling, cartilage erosion and immune cell infiltration. Both prophylactic and therapeutic treatment with meloxicam effectively reduced swelling (ankle circumference), oedema and extravasation of Evans blue dye in the affected joint. Moreover, meloxicam reduced loss in range of motion and also reduced mechanical stimulus evoked pain scores. Notably, these effects persisted after discontinuing drug treatment.
The present study provides a unique comparison of prophylactic versus therapeutic effects of meloxicam in the CFA-induced model of monoarthritis.
本研究的目的是确定美洛昔康预防和治疗对完全弗氏佐剂(CFA)诱导的单关节炎的影响。
首先通过检查 CFA 注射到胫跗关节后多个水平的关节变化来确定该动物模型的有效性。然后,在单独的动物组中,在第 0-7 天(预防)和第 7-16 天(治疗)给予美洛昔康(5mg/kg)或载体。
CFA 注射关节表现出特征性的组织学和结构变化,如滑膜形成、骨重塑、软骨侵蚀和免疫细胞浸润。美洛昔康的预防和治疗均能有效减轻受累关节肿胀(踝关节周长)、水肿和 Evans 蓝染料外渗。此外,美洛昔康还降低了运动范围的丧失,并降低了机械刺激诱发的疼痛评分。值得注意的是,这些效果在停止药物治疗后仍然存在。
本研究提供了 CFA 诱导的单关节炎模型中美洛昔康预防与治疗效果的独特比较。